Market reactionShares fell 11% on Nov 5.
Erasca is a clinical-stage company developing ERAS-0015, a daily pill that blocks many forms of the RAS cancer protein, for lung, pancreatic and colorectal cancers; it is not approved.
Erasca's case rests on ERAS-0015, a once-daily oral molecular glue that blocks many RAS mutants, which produced unconfirmed responses in 62% of 37 previously treated KRAS G12X lung cancer patients. These early, uncontrolled results lead into a potentially registration-enabling lung cancer trial in 1H 2027 and Phase 3 trials in pancreatic and lung cancer in 2027. Revolution Medicines alleges that ERAS-0015 infringes one of its patents, which Erasca calls without merit. A July offering of about $632.5 million gross is expected to fund its planned milestones.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Registration-enabling lung cancer trial starts in 1H 2027
Do confirmed responses and durability in the expansion cohorts support starting the registration-enabling lung cancer trial on time?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Erasca's pan-RAS molecular glue ERAS-0015 showed early responses in lung and pancreatic cancer and three Phase 3 starts are planned from 2027; Revolution Medicines alleges patent infringement, which Erasca disputes
Pan-RAS molecular glue ERAS-0015 posts a 62% unconfirmed response rate in lung cancer Phase 1; Revolution Medicines' patent allegations are the main risk to development
Pan-RAS molecular glue posts 62% response rates in NSCLC Phase 1, but a patent dispute with Revolution Medicines could disrupt development before Phase 3 begins
AURORAS-1 & JYP0015M101 ERAS-0015 Phase 1 preliminary data
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Lung cancer, Gastrointestinal cancers, Other cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
13 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.